191 related articles for article (PubMed ID: 24270984)
1. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice.
Geerling JJ; Boon MR; van der Zon GC; van den Berg SA; van den Hoek AM; Lombès M; Princen HM; Havekes LM; Rensen PC; Guigas B
Diabetes; 2014 Mar; 63(3):880-91. PubMed ID: 24270984
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.
Bijland S; Pieterman EJ; Maas AC; van der Hoorn JW; van Erk MJ; van Klinken JB; Havekes LM; van Dijk KW; Princen HM; Rensen PC
J Biol Chem; 2010 Aug; 285(33):25168-75. PubMed ID: 20501652
[TBL] [Abstract][Full Text] [Related]
3. Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue.
den Boer MA; Berbée JF; Reiss P; van der Valk M; Voshol PJ; Kuipers F; Havekes LM; Rensen PC; Romijn JA
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):124-9. PubMed ID: 16269669
[TBL] [Abstract][Full Text] [Related]
4. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
de Vries-van der Weij J; de Haan W; Hu L; Kuif M; Oei HL; van der Hoorn JW; Havekes LM; Princen HM; Romijn JA; Smit JW; Rensen PC
Endocrinology; 2009 May; 150(5):2368-75. PubMed ID: 19147676
[TBL] [Abstract][Full Text] [Related]
5. FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues.
Schlein C; Talukdar S; Heine M; Fischer AW; Krott LM; Nilsson SK; Brenner MB; Heeren J; Scheja L
Cell Metab; 2016 Mar; 23(3):441-53. PubMed ID: 26853749
[TBL] [Abstract][Full Text] [Related]
6. Brown adipose tissue takes up plasma triglycerides mostly after lipolysis.
Khedoe PP; Hoeke G; Kooijman S; Dijk W; Buijs JT; Kersten S; Havekes LM; Hiemstra PS; Berbée JF; Boon MR; Rensen PC
J Lipid Res; 2015 Jan; 56(1):51-9. PubMed ID: 25351615
[TBL] [Abstract][Full Text] [Related]
7. USF1 deficiency activates brown adipose tissue and improves cardiometabolic health.
Laurila PP; Soronen J; Kooijman S; Forsström S; Boon MR; Surakka I; Kaiharju E; Coomans CP; Van Den Berg SA; Autio A; Sarin AP; Kettunen J; Tikkanen E; Manninen T; Metso J; Silvennoinen R; Merikanto K; Ruuth M; Perttilä J; Mäkelä A; Isomi A; Tuomainen AM; Tikka A; Ramadan UA; Seppälä I; Lehtimäki T; Eriksson J; Havulinna A; Jula A; Karhunen PJ; Salomaa V; Perola M; Ehnholm C; Lee-Rueckert M; Van Eck M; Roivainen A; Taskinen MR; Peltonen L; Mervaala E; Jalanko A; Hohtola E; Olkkonen VM; Ripatti S; Kovanen PT; Rensen PC; Suomalainen A; Jauhiainen M
Sci Transl Med; 2016 Jan; 8(323):323ra13. PubMed ID: 26819196
[TBL] [Abstract][Full Text] [Related]
8. Cholesteryl ester transfer protein (CETP) increases postprandial triglyceridaemia and delays triacylglycerol plasma clearance in transgenic mice.
Salerno AG; Patrício PR; Berti JA; Oliveira HC
Biochem J; 2009 May; 419(3):629-34. PubMed ID: 19191759
[TBL] [Abstract][Full Text] [Related]
9. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.
Schaap FG; Rensen PC; Voshol PJ; Vrins C; van der Vliet HN; Chamuleau RA; Havekes LM; Groen AK; van Dijk KW
J Biol Chem; 2004 Jul; 279(27):27941-7. PubMed ID: 15090553
[TBL] [Abstract][Full Text] [Related]
10. Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes.
Johansen RF; Søndergaard E; Linnebjerg H; Garhyan P; Lam ECQ; Porksen N; Jacober SJ; Nielsen S
Diabetes Obes Metab; 2018 Feb; 20(2):419-426. PubMed ID: 28817248
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of apolipoprotein E isoforms on lipolysis of very low-density lipoprotein triglycerides.
Hara M; Iso-O N; Satoh H; Noto H; Togo M; Ishibashi S; Kimura S; Kadowaki T; Hashimoto Y; Tsukamoto K
Metabolism; 2006 Aug; 55(8):1129-34. PubMed ID: 16839851
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron-induced brown fat activation does not exacerbate atherosclerosis in mice with a functional hepatic ApoE-LDLR pathway.
Ying Z; van Eenige R; Beerepoot R; Boon MR; Kloosterhuis NJ; van de Sluis B; Bartelt A; Rensen PCN; Kooijman S
Pharmacol Res; 2023 Jan; 187():106634. PubMed ID: 36574856
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
Hoeke G; Wang Y; van Dam AD; Mol IM; Gart E; Klop HG; van den Berg SM; Pieterman EH; Princen HMG; Groen AK; Rensen PCN; Berbée JFP; Boon MR
Atherosclerosis; 2017 Dec; 267():116-126. PubMed ID: 29121499
[TBL] [Abstract][Full Text] [Related]
14. Progression of Chronic Kidney Disease Affects HDL Impact on Lipoprotein Lipase (LPL)-Mediated VLDL Lipolysis Efficiency.
Ćwiklińska A; Cackowska M; Wieczorek E; Król E; Kowalski R; Kuchta A; Kortas-Stempak B; Gliwińska A; Dąbkowski K; Zielińska J; Dębska-Ślizień A; Jankowski M
Kidney Blood Press Res; 2018; 43(3):970-978. PubMed ID: 29913451
[TBL] [Abstract][Full Text] [Related]
15. Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production.
Nourbakhsh M; Douglas DN; Pu CH; Lewis JT; Kawahara T; Lisboa LF; Wei E; Asthana S; Quiroga AD; Law LM; Chen C; Addison WR; Nelson R; Houghton M; Lehner R; Kneteman NM
J Hepatol; 2013 Aug; 59(2):336-43. PubMed ID: 23542347
[TBL] [Abstract][Full Text] [Related]
16. Essential fatty acid deficiency in mice is associated with hepatic steatosis and secretion of large VLDL particles.
Werner A; Havinga R; Bos T; Bloks VW; Kuipers F; Verkade HJ
Am J Physiol Gastrointest Liver Physiol; 2005 Jun; 288(6):G1150-8. PubMed ID: 15662048
[TBL] [Abstract][Full Text] [Related]
17. Salsalate activates brown adipose tissue in mice.
van Dam AD; Nahon KJ; Kooijman S; van den Berg SM; Kanhai AA; Kikuchi T; Heemskerk MM; van Harmelen V; Lombès M; van den Hoek AM; de Winther MP; Lutgens E; Guigas B; Rensen PC; Boon MR
Diabetes; 2015 May; 64(5):1544-54. PubMed ID: 25475439
[TBL] [Abstract][Full Text] [Related]
18. Aging-associated reductions in lipolytic and mitochondrial proteins in mouse adipose tissue are not rescued by metformin treatment.
Mennes E; Dungan CM; Frendo-Cumbo S; Williamson DL; Wright DC
J Gerontol A Biol Sci Med Sci; 2014 Sep; 69(9):1060-8. PubMed ID: 24127429
[TBL] [Abstract][Full Text] [Related]
19. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E- deficient mouse hepatocytes.
Kuipers F; Jong MC; Lin Y; Eck M; Havinga R; Bloks V; Verkade HJ; Hofker MH; Moshage H; Berkel TJ; Vonk RJ; Havekes LM
J Clin Invest; 1997 Dec; 100(11):2915-22. PubMed ID: 9389759
[TBL] [Abstract][Full Text] [Related]
20. Regulation of plasma triglycerides in insulin resistance and diabetes.
Ginsberg HN; Zhang YL; Hernandez-Ono A
Arch Med Res; 2005; 36(3):232-40. PubMed ID: 15925013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
